Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Molecular profiling of clear cell adenocarcinoma of the urinary tract.

Lin CY, Saleem A, Stehr H, Zehnder JL, Pinsky BA, Kunder CA.

Virchows Arch. 2019 Aug 2. doi: 10.1007/s00428-019-02634-5. [Epub ahead of print]

PMID:
31372739
2.

Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.

Kumar J, Butzmann A, Wu S, Easly S, Zehnder JL, Warnke RA, Bangs CD, Jangam D, Cherry A, Lau J, Nybakken G, Ohgami RS.

Am J Surg Pathol. 2019 Jul 29. doi: 10.1097/PAS.0000000000001338. [Epub ahead of print]

PMID:
31368914
3.

Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.

Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, Zehnder JL.

Haematologica. 2019 Jul 11. pii: haematol.2019.226688. doi: 10.3324/haematol.2019.226688. [Epub ahead of print]

4.

Implementation of Whole-Blood Impedance Aggregometry for Heparin-Induced Thrombocytopenia Functional Assay and Case Discussion.

Jin J, Baker SA, Hall ET, Gombar S, Bao A, Zehnder JL.

Am J Clin Pathol. 2019 Jun 5;152(1):50-58. doi: 10.1093/ajcp/aqz013.

PMID:
31165165
5.

Update on diagnostic testing for platelet function disorders: What is practical and useful?

Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL.

Int J Lab Hematol. 2019 May;41 Suppl 1:26-32. doi: 10.1111/ijlh.12995. Review.

PMID:
31069975
6.

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.

Li P, Shahmarvand N, Lynch D, Gotlib JR, Merker JD, Zehnder JL, George TI, Ohgami RS.

Int J Lab Hematol. 2019 Jun;41(3):345-352. doi: 10.1111/ijlh.12981. Epub 2019 Feb 27.

PMID:
30811101
7.

Structural Variation Detection by Proximity Ligation from Formalin-Fixed, Paraffin-Embedded Tumor Tissue.

Troll CJ, Putnam NH, Hartley PD, Rice B, Blanchette M, Siddiqui S, Ganbat JO, Powers MP, Ramakrishnan R, Kunder CA, Bustamante CD, Zehnder JL, Green RE, Costa HA.

J Mol Diagn. 2019 May;21(3):375-383. doi: 10.1016/j.jmoldx.2018.11.003. Epub 2018 Dec 31.

8.

MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing.

Schneidawind C, Jeong J, Schneidawind D, Kim IS, Duque-Afonso J, Wong SHK, Iwasaki M, Breese EH, Zehnder JL, Porteus M, Cleary ML.

Blood Adv. 2018 Apr 24;2(8):832-845. doi: 10.1182/bloodadvances.2017013748.

9.

Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case.

Tavallaee M, Steiner DF, Zehnder JL, Folkins AK, Karam AK.

Int J Gynecol Pathol. 2019 Jul;38(4):386-392. doi: 10.1097/PGP.0000000000000507.

PMID:
29620581
10.

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S, Ohgami RS.

Blood Adv. 2018 Mar 13;2(5):481-491. doi: 10.1182/bloodadvances.2017009654.

11.

Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.

Yang SR, Lin CY, Stehr H, Long SR, Kong CS, Berry GJ, Zehnder JL, Kunder CA.

J Mol Diagn. 2018 Mar;20(2):184-194. doi: 10.1016/j.jmoldx.2017.10.007. Epub 2017 Dec 19.

PMID:
29269277
12.

A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.

Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD.

Cancer Genet. 2017 Oct;216-217:10-15. doi: 10.1016/j.cancergen.2017.05.001. Epub 2017 May 10.

PMID:
29025582
13.

IDH2 Mutation in a Patient with Metastatic Colon Cancer.

Zhang BM, Aleshin A, Lin CY, Ford J, Zehnder JL, Suarez CJ.

N Engl J Med. 2017 May 18;376(20):1991-2. doi: 10.1056/NEJMc1701072. No abstract available.

PMID:
28514606
14.

A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.

Shahmarvand N, Oak JS, Cascio MJ, Alcasid M, Goodman E, Medeiros BC, Arber DA, Zehnder JL, Ohgami RS.

Int J Lab Hematol. 2017 Aug;39(4):375-383. doi: 10.1111/ijlh.12636. Epub 2017 Apr 19.

PMID:
28422420
15.

Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.

Costa HA, Neal JW, Bustamante CD, Zehnder JL.

Mol Diagn Ther. 2017 Aug;21(4):431-436. doi: 10.1007/s40291-017-0275-y.

16.

Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use.

Xu L, You X, Zheng P, Zhang BM, Gupta PK, Lavori P, Meyer E, Zehnder JL.

J Mol Diagn. 2017 Jan;19(1):72-83. doi: 10.1016/j.jmoldx.2016.07.009. Epub 2016 Nov 1.

17.

Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.

Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson JA, Klein TE, Bustamante CD, Roden DM, Shaffer C, Denny JC, Zehnder JL, Altman RB.

Mol Genet Genomic Med. 2016 Jun 21;4(5):513-20. doi: 10.1002/mgg3.226. eCollection 2016 Sep.

18.

ROS: novel regulators of thrombopoiesis.

Zhang B, Zehnder JL.

Blood. 2016 Aug 4;128(5):613-4. doi: 10.1182/blood-2016-06-718544. No abstract available.

19.

Prozone Effect in the Diagnosis of Lupus Anticoagulant for the Lupus Anticoagulant-Hypoprothrombinemia Syndrome.

Jin J, Zehnder JL.

Am J Clin Pathol. 2016 Aug;146(2):262-7. doi: 10.1093/ajcp/aqw106.

PMID:
27473743
20.

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, Mountain JL, Francke U, Tung JY, Nguyen HM, Zhang H, Gojenola L, Zehnder JL, Gotlib J.

Blood. 2016 Aug 25;128(8):1121-8. doi: 10.1182/blood-2015-06-652941. Epub 2016 Jun 30.

21.

A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.

Ozawa MG, Bhaduri A, Chisholm KM, Baker SA, Ma L, Zehnder JL, Luna-Fineman S, Link MP, Merker JD, Arber DA, Ohgami RS.

Mod Pathol. 2016 Oct;29(10):1212-20. doi: 10.1038/modpathol.2016.102. Epub 2016 Jun 24.

22.

Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.

Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB.

Am J Hematol. 2016 Sep;91(9):907-11. doi: 10.1002/ajh.24434. Epub 2016 Jun 20.

23.

Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications.

Nybakken GE, Bala R, Gratzinger D, Jones CD, Zehnder JL, Bangs CD, Cherry A, Warnke RA, Natkunam Y.

PLoS One. 2016 Mar 18;11(3):e0151735. doi: 10.1371/journal.pone.0151735. eCollection 2016.

24.

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP.

Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13.

25.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms.

Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JL.

Arch Pathol Lab Med. 2016 Jul;140(7):675-7. doi: 10.5858/arpa.2015-0400-CP. Epub 2015 Dec 11. No abstract available.

26.

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)).

Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JL.

Arch Pathol Lab Med. 2016 Jul;140(7):672-4. doi: 10.5858/arpa.2015-0399-CP. Epub 2015 Dec 11. No abstract available.

PMID:
26653363
27.

Factor V Leiden.

Van Cott EM, Khor B, Zehnder JL.

Am J Hematol. 2016 Jan;91(1):46-9. doi: 10.1002/ajh.24222. Epub 2015 Nov 17. Review.

28.

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

Khodadoust MS, Luo B, Medeiros BC, Johnson RC, Ewalt MD, Schalkwyk AS, Bangs CD, Cherry AM, Arai S, Arber DA, Zehnder JL, Gotlib J.

Leukemia. 2016 Apr;30(4):947-50. doi: 10.1038/leu.2015.136. Epub 2015 Jun 9. No abstract available.

29.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.

30.

Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.

Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RS.

Am J Clin Pathol. 2015 Apr;143(4):527-34. doi: 10.1309/AJCPZ3J4GEEYIRRA.

PMID:
25780004
31.

The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma.

Karnik T, Ozawa MG, Lefterova M, Luna-Fineman S, Alvarez E, Link M, Zehnder JL, Arber DA, Ohgami RS.

Hum Pathol. 2015 Apr;46(4):629-33. doi: 10.1016/j.humpath.2014.12.016. Epub 2015 Jan 29.

PMID:
25701230
32.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.

Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.

33.

A Balanced Look at the Implications of Genomic (and Other "Omics") Testing for Disease Diagnosis and Clinical Care.

Boyd SD, Galli SJ, Schrijver I, Zehnder JL, Ashley EA, Merker JD.

Genes (Basel). 2014 Sep 1;5(3):748-66. doi: 10.3390/genes5030748.

34.

Identification of recurrent SMO and BRAF mutations in ameloblastomas.

Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, Qu K, Gong X, Ng T, Jones CD, Varma S, Odegaard JI, Sugiyama T, Koyota S, Rubin BP, Troxell ML, Pelham RJ, Zehnder JL, Beachy PA, Pollack JR, West RB.

Nat Genet. 2014 Jul;46(7):722-5. doi: 10.1038/ng.2986. Epub 2014 May 25. Erratum in: Nat Genet. 2015 Jan;47(1):97.

35.

STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA.

Haematologica. 2014 Jul;99(7):e105-7. doi: 10.3324/haematol.2013.101543. Epub 2014 May 16. No abstract available.

36.

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13. doi: 10.1016/j.bbmt.2014.04.018. Epub 2014 Apr 24.

37.

High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies.

Garritsen HS, Probst-Kepper M, Legath N, Eberl W, Samaniego S, Woudenberg J, Schuitemaker JH, Kroll H, Gurney DA, Moore GW, Zehnder JL.

Int J Lab Hematol. 2014 Apr;36(2):135-43. doi: 10.1111/ijlh.12136. Epub 2013 Aug 28.

PMID:
23981347
38.

Oxidative stress and immune thrombocytopenia.

Zhang B, Zehnder JL.

Semin Hematol. 2013 Jul;50(3):e1-4. doi: 10.1053/j.seminhematol.2013.06.011.

39.

Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.

Merker JD, Roskin KM, Ng D, Pan C, Fisk DG, King JJ, Hoh R, Stadler M, Okumoto LM, Abidi P, Hewitt R, Jones CD, Gojenola L, Clark MJ, Zhang B, Cherry AM, George TI, Snyder M, Boyd SD, Zehnder JL, Fire AZ, Gotlib J.

Haematologica. 2013 Nov;98(11):1689-96. doi: 10.3324/haematol.2013.092379. Epub 2013 Jul 19.

40.

A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.

Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL, Strober S, Lavori P, Miklos DB, Johnson DS, Negrin RS.

Blood. 2013 Jun 13;121(24):4955-62. doi: 10.1182/blood-2013-03-489757. Epub 2013 May 7.

41.

Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma.

Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA.

Adv Anat Pathol. 2013 May;20(3):137-40. doi: 10.1097/PAP.0b013e31828d17ec. Review.

PMID:
23574769
42.

STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia.

Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA.

Leukemia. 2013 Nov;27(11):2244-7. doi: 10.1038/leu.2013.104. Epub 2013 Apr 8. No abstract available.

PMID:
23563237
43.

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB.

Leukemia. 2013 Aug;27(8):1659-65. doi: 10.1038/leu.2013.52. Epub 2013 Feb 19.

44.

Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.

Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL.

Ann Pharmacother. 2013 Feb;47(2):151-8. doi: 10.1345/aph.1R635. Epub 2013 Feb 5.

PMID:
23386070
45.

TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma.

Ohgami RS, Zhao S, Ohgami JK, Leavitt MO, Zehnder JL, West RB, Arber DA, Natkunam Y, Warnke RA.

Am J Surg Pathol. 2012 Nov;36(11):1619-28. doi: 10.1097/PAS.0b013e318264e223.

PMID:
23060347
46.

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet].

Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford RS.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May.

47.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB.

Blood. 2012 Jun 21;119(25):6145-54. doi: 10.1182/blood-2011-12-395970. Epub 2012 May 4.

48.

Aggressive EBV-associated lymphoproliferative disorder: a prodrome to diffuse large B-cell lymphoma?

Batra R, Medeiros BC, Zehnder JL, Warnke RA, Natkunam Y.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):325-30. doi: 10.1097/PAI.0b013e318233d72a.

PMID:
22505014
49.

A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.

Zhang B, Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J.

Blood. 2011 Dec 22;118(26):6988-90. doi: 10.1182/blood-2011-10-386177. No abstract available.

50.

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buño I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21194-9. doi: 10.1073/pnas.1118357109. Epub 2011 Dec 12.

Supplemental Content

Loading ...
Support Center